We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > polyphor

News List

MHRA approves Polyphor’s phase 1 trial of novel inhaled antibiotic pharmatimes
December 23, 2020
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Swiss biotech Polyphor’s first-in-human phase I study of its novel inhaled antibiotic murepavadin.
Balixafortide combination with eribulin in metastatic breast cancer data presented at ESMO 2018 show consistent positive trend for all efficacy endpoints, including overall survival firstwordpharma
October 25, 2018
Balixafortide combination with eribulin in metastatic breast cancer data presented at ESMO 2018 show consistent positive trend for all efficacy endpoints, including overall survival
Polyphor launches the development of an inhaled antibiotic murepavadin europeanpharmaceuticalreview
October 13, 2017
Polyphor Ltd has announced €5m funding, in order to support and accelerate the development of an inhaled dosage form of murepavadin…